Automated Insulin for Management of Intrapartum Glycemia

Automated Insulin for Management of Intrapartum Glycemia (AIMING): a Multicenter Randomized Controlled Trial

The goal of this clinical trial is learn if automated insulin delivery (AID) systems can be used for glucose management during labor/delivery for pregnant people with type 1 diabetes (T1D). The main questions this study aims to answer are

• What are the neonatal glycemic outcomes with use of AID systems during labor/delivery?
• Do patients report higher birth satisfaction with use of AID systems during labor/delivery?
• Are glycemic parameters like time-in-range (TIR) better with use of AID systems during labor/delivery?

Researchers will compare AID systems to intravenous (IV) insulin (the current standard of care for glucose management during labor/delivery) by randomly assigning participants to one or the other.

Inclusion Criteria:

• Currently pregnant at ≥ 34 weeks
• Known diagnosis of type 1 diabetes ≥ 1 year
• Use of commercially available AID system since at least 28 weeks gestation
• Singleton pregnancy
• English- or Spanish-speaking

Exclusion Criteria:

• Multifetal gestation
• Planned cesarean delivery
• Use of medications known to interfere with glucose metabolism
• Intrauterine fetal demise
• Physical or psychological disease likely to interfere with the conduct of the study and/or the ability to participate in own healthcare